Login / Signup

Use of Patient Preferences Data Regarding Multiple Risks to Inform Regulatory Decisions.

J Felipe Montano-CamposJuan Marcos GonzalezTimothy RickertAngelyn Otteson FairchildBennett LevitanShelby D Reed
Published in: MDM policy & practice (2023)
Estimates of maximum acceptable risk (MAR) for a defined treatment benefit can be useful to inform regulatory decisions; however, the conventional metric considers one adverse event at a time.This article applies a new approach known as SMART (simultaneous maximum acceptable risk thresholds) that accounts for multiple adverse events to 3 published discrete-choice experiments.Findings reveal that conventional MARs could lead decision makers to accept a treatment based on individual risks that would not be acceptable if multiple risks are considered simultaneously.
Keyphrases
  • human health
  • decision making
  • gene expression
  • emergency department
  • systematic review
  • genome wide
  • electronic health record
  • dna methylation
  • combination therapy
  • single cell
  • big data